Influence of NOS1 on verbal intelligence and working memory in both patients with schizophrenia and healthy control subjects.

CONTEXT Human and animal studies have implicated the gene NOS1 in both cognition and schizophrenia susceptibility. OBJECTIVE To investigate whether a potential schizophrenia risk single-nucleotide polymorphism (rs6490121) identified in a recent genome-wide association study negatively influences cognition in patients with schizophrenia and healthy control subjects. DESIGN A comparison of both cases and controls grouped according to NOS1 genotype (GG vs AG vs AA) on selected measures of cognition in 2 independent samples. We tested for association between NOS1 rs6490121 and cognitive functions known to be impaired in schizophrenia (IQ, episodic memory, working memory, and attentional control) in an Irish sample. We then sought to replicate the significant results in a German sample. SETTING Unrelated patients from general adult psychiatric inpatient and outpatient services and unrelated healthy volunteers from the general population were ascertained. PARTICIPANTS Patients with DSM-IV-diagnosed schizophrenia and healthy control subjects from independent samples of Irish (cases, n = 349; controls, n = 230) and German (cases, n = 232; controls, n = 1344) nationality. RESULTS A main effect of NOS1 genotype on verbal IQ and working memory was observed in the Irish sample where the homozygous carriers of the schizophrenia risk G allele performed poorly compared with the other genotype groups. These findings were replicated in the German sample, again with the GG genotype carriers performing below other genotype groups. Post hoc analysis of additional IQ measures (full-scale and performance IQ) in the German sample revealed that NOS1 GG carriers underperformed on these measures also. CONCLUSIONS NOS1 is associated with clinically significant variation in cognition. Whether this is a mechanism by which schizophrenia risk is increased (eg, via an influence on cognitive reserve) is yet to be confirmed.

[1]  J. Stockman.  Recurrent Rearrangements of Chromosome 1q21.1 and Variable Pediatric Phenotypes , 2010 .

[2]  Christian von Mering,et al.  STRING 8—a global view on proteins and their functional interactions in 630 organisms , 2008, Nucleic Acids Res..

[3]  Ann-Christine Ehlis,et al.  Influence of functional variant of neuronal nitric oxide synthase on impulsive behaviors in humans. , 2009, Archives of general psychiatry.

[4]  Lin He,et al.  Evidence for association between the 5' flank of the NOS1 gene and schizophrenia in the Chinese population. , 2008, The international journal of neuropsychopharmacology.

[5]  P. Visscher,et al.  Rare chromosomal deletions and duplications increase risk of schizophrenia , 2008, Nature.

[6]  Thomas W. Mühleisen,et al.  Large recurrent microdeletions associated with schizophrenia , 2008, Nature.

[7]  C. Spencer,et al.  Identification of loci associated with schizophrenia by genome-wide association and follow-up , 2008, Nature Genetics.

[8]  Marcus R. Munafò,et al.  Meta-Analysis of the Cognitive Effects of the Catechol-O-Methyltransferase Gene Val158/108Met Polymorphism , 2008, Biological Psychiatry.

[9]  G. Feng,et al.  Family-based association studies of CAPON and schizophrenia in the Chinese Han population , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[10]  A. Fanous,et al.  Genetics of clinical features and subtypes of schizophrenia: A review of the recent literature , 2008, Current psychiatry reports.

[11]  A. Singleton,et al.  Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia , 2008, Science.

[12]  P. Sullivan.  Schizophrenia genetics: the search for a hard lead , 2008, Current opinion in psychiatry.

[13]  M. Gill,et al.  A dysbindin risk haplotype associated with less severe manic-type symptoms in psychosis , 2008, Neuroscience Letters.

[14]  R. Feil,et al.  NO/cGMP-dependent modulation of synaptic transmission. , 2008, Handbook of experimental pharmacology.

[15]  M. Gill,et al.  Variance in neurocognitive performance is associated with dysbindin-1 in schizophrenia: A preliminary study , 2007, Neuropsychologia.

[16]  Todd Lencz,et al.  Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia , 2007, Proceedings of the National Academy of Sciences.

[17]  M. Moreau,et al.  Association of synapsin 2 with schizophrenia in families of Northern European ancestry , 2007, Schizophrenia Research.

[18]  Andreas Buchmann,et al.  Calmodulin-binding transcription activator 1 (CAMTA1) alleles predispose human episodic memory performance. , 2007, Human molecular genetics.

[19]  H. Herken,et al.  Increased Levels of Nitric Oxide, Cortisol and Adrenomedullin in Patients with Chronic Schizophrenia , 2007, Medical Principles and Practice.

[20]  山田 立子,et al.  No genetic association between postsynaptic density-95 gene polymorphisms and schizophrenia , 2007 .

[21]  Kim Fejgin,et al.  The amino acid l-lysine blocks the disruptive effect of phencyclidine on prepulse inhibition in mice , 2007, Psychopharmacology.

[22]  T. Archer,et al.  Phencyclidine affects memory in a nitric oxide-dependent manner: Working and reference memory , 2006, Behavioural Brain Research.

[23]  Sarah A. J. Reading,et al.  Neurobiology of Schizophrenia , 2006, Neuron.

[24]  A. Meyer-Lindenberg,et al.  Intermediate phenotypes and genetic mechanisms of psychiatric disorders , 2006, Nature Reviews Neuroscience.

[25]  Trevor Archer,et al.  Effects of phencyclidine on spatial learning and memory: Nitric oxide-dependent mechanisms , 2006, Behavioural Brain Research.

[26]  M. Gill,et al.  Are deficits in executive sub-processes simply reflecting more general cognitive decline in schizophrenia? , 2006, Schizophrenia Research.

[27]  Birgit Funke,et al.  Genetic variation in DTNBP1 influences general cognitive ability. , 2006, Human molecular genetics.

[28]  B. Sahakian,et al.  Cognitive reserve in neuropsychiatry , 2006, Psychological Medicine.

[29]  U. Förstermann,et al.  Transcription of human neuronal nitric oxide synthase mRNAs derived from different first exons is partly controlled by exon 1-specific promoter sequences. , 2006, Genomics.

[30]  Andreas Papassotiropoulos,et al.  Identification of a genetic cluster influencing memory performance and hippocampal activity in humans. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D Saur,et al.  A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function , 2006, Molecular Psychiatry.

[32]  H. Gurling,et al.  Failure to Confirm Allelic Association Between Markers at the CAPON Gene Locus and Schizophrenia in a British Sample , 2006, Biological Psychiatry.

[33]  S. Tsai,et al.  Association study of polymorphisms in post-synaptic density protein 95 (PSD-95) with schizophrenia , 2006, Journal of Neural Transmission.

[34]  R. Huganir,et al.  Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. , 2005, American journal of human genetics.

[35]  Philip D. Harvey,et al.  Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophrenia. , 2005, Archives of general psychiatry.

[36]  Jörgen A. Engel,et al.  Effects of phencyclidine on acoustic startle and prepulse inhibition in neuronal nitric oxide synthase deficient mice , 2005, European Neuropsychopharmacology.

[37]  C. Ommen.  Putting the PC in IQ: Images in the Weschler Adult Intelligence Scale – Third Edition (WAIS III) , 2005 .

[38]  Hiroki Shibata,et al.  Association study of polymorphisms in synaptic vesicle-associated genes, SYN2 and CPLX2, with schizophrenia , 2005, Behavioral and Brain Functions.

[39]  Shi-yu Guo,et al.  The role of norepinephrine and nitric oxide in activities of rat arginine vasopressin neurons in response to immune challenge , 2005, Neuroscience Letters.

[40]  Lin He,et al.  Association of the carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase gene with schizophrenia in the Chinese Han population. , 2005, Biochemical and biophysical research communications.

[41]  Paul J. Harrison,et al.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence , 2005, Molecular Psychiatry.

[42]  Mario Engelmann,et al.  Impaired cognitive performance in neuronal nitric oxide synthase knockout mice is associated with hippocampal protein derangements. , 2004, Nitric oxide : biology and chemistry.

[43]  J. Engel,et al.  The neuronal selective nitric oxide synthase inhibitor, Nomega-propyl-L-arginine, blocks the effects of phencyclidine on prepulse inhibition and locomotor activity in mice. , 2004, European journal of pharmacology.

[44]  B. Uyanık,et al.  Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. , 2004, Archives of medical research.

[45]  Jörgen A. Engel,et al.  Habituation of acoustic startle is disrupted by psychotomimetic drugs: differential dependence on dopaminergic and nitric oxide modulatory mechanisms , 2004, Psychopharmacology.

[46]  Mario Engelmann,et al.  Neuronal nitric oxide synthase knock-out mice show impaired cognitive performance. , 2004, Nitric oxide : biology and chemistry.

[47]  A. Bassett,et al.  Linkage disequilibrium mapping of schizophrenia susceptibility to the CAPON region of chromosome 1q22. , 2004, American journal of human genetics.

[48]  P. Emson,et al.  Expression of nNOS and soluble guanylate cyclase in schizophrenic brain , 2004, Neuroreport.

[49]  J. Engel,et al.  Phencyclidine-induced behaviour in mice prevented by methylene blue. , 2004, Basic & clinical pharmacology & toxicology.

[50]  馬場 元.  Expression of nNOS and soluble guanylate cyclase in schizophrenic brain , 2004 .

[51]  Adam J. Smith,et al.  The Database of Interacting Proteins: 2004 update , 2004, Nucleic Acids Res..

[52]  Martin Vingron,et al.  IntAct: an open source molecular interaction database , 2004, Nucleic Acids Res..

[53]  Shih-Jen Tsai,et al.  Association analysis for the CA repeat polymorphism of the neuronal nitric oxide synthase (NOS1) gene and schizophrenia , 2003, Schizophrenia Research.

[54]  M. Skolnick,et al.  Predisposition locus for major depression at chromosome 12q22-12q23.2. , 2003, American journal of human genetics.

[55]  I. Gottesman,et al.  The endophenotype concept in psychiatry: etymology and strategic intentions. , 2003, The American journal of psychiatry.

[56]  U. Förstermann,et al.  Transcription of Different Exons 1 of the Human Neuronal Nitric Oxide Synthase Gene Is Dynamically Regulated in a Cell- and Stimulus- Specific Manner , 2003, Biological chemistry.

[57]  R. Plomin.  Genetics, genes, genomics and g , 2003, Molecular Psychiatry.

[58]  Asaf Caspi,et al.  A population-based cohort study of premorbid intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective disorder, and nonpsychotic bipolar disorder. , 2002, The American journal of psychiatry.

[59]  Dimitris Fouskakis,et al.  Associations between premorbid intellectual performance, early-life exposures and early-onset schizophrenia , 2002, British Journal of Psychiatry.

[60]  K. Hornik,et al.  Genome scan for susceptibility loci for schizophrenia and bipolar disorder , 2002, Biological Psychiatry.

[61]  Richie Poulton,et al.  Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. , 2002, Archives of general psychiatry.

[62]  John Stewart,et al.  A genome-wide scan for linkage to chromosomal regions in 382 sibling pairs with schizophrenia or schizoaffective disorder. , 2002, The American journal of psychiatry.

[63]  Robert Plomin,et al.  Genetics and general cognitive ability (g) , 2002, Trends in Cognitive Sciences.

[64]  T. Shinkai,et al.  Allelic association of the neuronal nitric oxide synthase (NOS1) gene with schizophrenia , 2002, Molecular Psychiatry.

[65]  R. Straub,et al.  Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Ioannis Xenarios,et al.  DIP: The Database of Interacting Proteins: 2001 update , 2001, Nucleic Acids Res..

[67]  Gary D Bader,et al.  BIND--The Biomolecular Interaction Network Database. , 2001, Nucleic acids research.

[68]  K. Hornik,et al.  Genome Scan for Susceptibility Loci for Schizophrenia , 2000, Neuropsychobiology.

[69]  I. Gottesman,et al.  Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. , 2000, American journal of medical genetics.

[70]  A Reichenberg,et al.  Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. , 1999, The American journal of psychiatry.

[71]  Randall W Engle,et al.  Working memory, short-term memory, and general fluid intelligence: a latent-variable approach. , 1999, Journal of experimental psychology. General.

[72]  Jörgen A. Engel,et al.  The nitric oxide synthase inhibitor. L-NAME, blocks certain phencyclidine-induced but not amphetamine-induced effects on behaviour and brain biochemistry in the rat , 1998, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[73]  M. Tsuang,et al.  IQ decline during childhood and adult psychotic symptoms in a community sample: a 19-year longitudinal study. , 1998, The American journal of psychiatry.

[74]  R. Heinrichs,et al.  Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. , 1998, Neuropsychology.

[75]  A. David,et al.  IQ and risk for schizophrenia: a population-based cohort study , 1997, Psychological Medicine.

[76]  D. Jackson,et al.  Nitric oxide synthase inhibition blocks phencyclidine-induced behavioural effects on prepulse inhibition and locomotor activity in the rat , 1997, Psychopharmacology.

[77]  M. First,et al.  Structured clinical interview for DSM-IV axis II personality disorders : SCID-II , 1997 .

[78]  Thomas R. Carretta,et al.  Cognitive-Components Tests Are Not Much More Than g: An Extension of Kyllonen's Analyses , 1996 .

[79]  J. Rice,et al.  Comparison of direct interview and family history diagnoses of alcohol dependence. , 1995, Alcoholism, clinical and experimental research.

[80]  S. Hirsch,et al.  Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. , 1995, Biochemical and biophysical research communications.

[81]  T. Crow,et al.  Childhood precursors of psychosis as clues to its evolutionary origins. , 1995, European archives of psychiatry and clinical neuroscience.

[82]  P. Marsden,et al.  Structural organization of the human neuronal nitric oxide synthase gene (NOS1). , 1994, The Journal of biological chemistry.

[83]  J J Kim,et al.  Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. , 1993, Archives of general psychiatry.

[84]  C A Sandman,et al.  Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. , 1993, Archives of general psychiatry.

[85]  Robert A. Bornstein,et al.  The Wechsler Memory Scale—Revised , 1990 .

[86]  N. Mimica,et al.  Scale for the Assessment of Negative Symptoms (SANS)* , 1989, British Journal of Psychiatry.

[87]  N. Risch,et al.  The continuous performance test, identical pairs version (CPT-IP): I. new findings about sustained attention in normal families , 1988, Psychiatry Research.

[88]  C. Reynolds,et al.  Wechsler memory scale-revised , 1988 .

[89]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.